An interventional study of I-TRANSFER-HF in Heart Failure, sponsored by Weill Medical College of Cornell University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Heart Failure by Weill Medical College of Cornell University — 5 open to participants now, 5 under way, none of them phase 3. Heart Failure · Weill Medical College of Cornell University.
Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, and was the 9th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 13 studies in Heart Failure by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 30 days–1 yrs
Weill Medical College of Cornell University · Sites in United States
Ages 65+
Weill Medical College of Cornell University · Sites in United States
Ages 65+
Weill Medical College of Cornell University · Sites in United States
Ages 60+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,094 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 40 across the 12 interventional studies, 33,100 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
4 of the studies in Heart Failure by Weill Medical College of Cornell University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05585125Weill Medical College of Cornell UniversityA Preliminary Study for INFORMED | 2027-02 |
| NCT07252310Weill Medical College of Cornell UniversityPilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App) | 2027-02 |
| NCT06587165Weill Medical College of Cornell UniversityQuantifying New Heart Muscle Cells | 2027-03-01 |
| NCT06118983Weill Medical College of Cornell UniversityImproving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Heart Failure by Weill Medical College of Cornell University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.
The study is interested in two questions:
The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.
The investigators' will test two hypotheses:
Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.
Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).
Aim 1, Inclusion Criteria:
Aim 1, Exclusion Criteria:
Aim 2, Inclusion Criteria:
- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Aim 2, Exclusion Criteria:
- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
This is a 1-year long intervention period when I-TRANSFER-HF is in operation.
Other: I-TRANSFER-HF
This is a baseline period of usual care (UC) with no intervention.
I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US.
All-cause 30-day hospital readmission
All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
Time frame: 30 days following post-Index HF Hospitalization
Number of Eligible patients
Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data
Time frame: 12 months
Number of Eligible Patients Who Received Protocol Components
Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data
Time frame: 12 months
Modality of outpatient follow-up
The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data
Time frame: 12 months
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data
Time frame: 12 months
Timeliness of Post-Hospital Outpatient Follow-Up
The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data
Time frame: 12 months
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
Feasibility will be assessed through qualitative interviews with site stakeholders
Time frame: 30 days after intervention (year of intervention)
Feasibility of implementing I-TRANSFER-HF (Surveys)
Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention.
Time frame: 30 days after intervention (year of intervention)
All-cause 30-day ED visits
All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data
Time frame: 30 days following post-Index heart failure Hospitalization.
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit.
Time frame: During a 12-month period (year of intervention)
Acceptability of I-TRANSFER-HF - Qualitative Interviews
Acceptability will be assessed through qualitative interviews.
Time frame: 30 days after intervention (year of intervention)
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention.
Time frame: 30 days after intervention (year of intervention)
Fidelity of I-TRANSFER-HF (Participant-Completed)
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process.
Time frame: 30 days after intervention (year of intervention)
Fidelity of I-TRANSFER-HF (Observational Ratings)
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process.
Time frame: 30 days after intervention (year of intervention)
Adaptation of I-TRANSFER-HF
Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period.
Time frame: 30 days after intervention (year of intervention)
Plan to share: No
Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 8 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →